Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
Top Cited Papers
- 17 March 2020
- journal article
- review article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (6), 724-744
- https://doi.org/10.1016/j.annonc.2020.03.285
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Fondation Leenaards
- Neos Therapeutics
This publication has 169 references indexed in Scilit:
- Tissue-Specific Actions of Glucocorticoids on Apoptosis: A Double-Edged SwordCells, 2013
- Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trialsAnnals Of The Rheumatic Diseases, 2012
- Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of responseAnnals Of The Rheumatic Diseases, 2012
- Spectrum of Cancer Risk Among US Solid Organ Transplant RecipientsJAMA, 2011
- Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndromeJournal of Allergy and Clinical Immunology, 2010
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumabRheumatology, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cellsNature Immunology, 2007
- Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndromeAnnals Of The Rheumatic Diseases, 2007
- A Tumorigenic Subpopulation with Stem Cell Properties in MelanomasCancer Research, 2005